Welcome!

News Feed Item

COPD Drug Market Opportunity and Clinical Pipeline Analysis

DALLAS, April 19, 2014 /PRNewswire/ --


ReportsnReports.com offers COPD Drug Market Opportunity & Clinical Pipeline Analysis 2014 to 2018 industry research report in its store at http://www.reportsnreports.com/reports/280894-copd-drug-market-opportunity-clinical-pipeline-analysis.html .

The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. Some of the drugs which are major contributors to this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. By 2018, it is expected that the combinations of LABA/LAMA would the leading drugs driving sales in the COPD therapy market and by 2021, these drugs would account for more than 25% of the market share. While in 2013, close to 50% of the global market was accounted by the US, with the other regions together accounting for 50%. However, it is expected that by 2018, the share of the USA would reduce marginally to 45%, while the lost share of this region would be taken over by the Asian region.

Companies discussed in COPD Drug Market Opportunity & Clinical Pipeline Analysis research report include Almirall, AstraZeneca, Boehringer Ingelheim, Bayer, Chiesi Farmaceutici, Forest Laboratories, Lallemand Pharma, Merck & Co, Novartis and Sunovion Pharmaceuticals. Order  a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=280894 .

Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death. The prevalence and incidence of this disease is increasing worldwide.

Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. Inspite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler.

ThisCOPD Drug Market Opportunity & Clinical Pipeline Analysis  Report Highlights:

• COPD Drug Market Overview
• COPD Patient Base: Global, US & Europe
• FDA & EMA Guidelines on Clinical Investigation of COPD Drugs
• COPD Drug Clinical Pipeline by Phase & Country
• COPD Drug in Development Phase: 174
• Majority of COPD Drugs in Preclinical Phase: 72
• Marketed COPD Drugs: 36
• Discontinued & Suspended COPD Drug Profiles

Other newly published reports on the pharmaceuticals industry available with us:

China Pharmaceutical Distribution Industry Report, 2013 market research says thanks to the continuous advancement in new medical reform, China's pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of roughly 20% in 2005-2013. Companies discussed in this report include China National Accord Medicines, Nanjing Pharmaceutical Co., Ltd (NPC), Chongqing Tongjunge, Shanghai No.1 Pharmacy, China National Medicines, Huadong Medicine, Cachet, Jointown, Realcan Pharmaceutical¸ Shanghai Pharma, Zhejiang Int'l Group, Zhejiang Zhenyuan and CNPIC. Complete report is available at http://www.reportsnreports.com/reports/280794-china-pharmaceutical-distribution-industry-report-2013.html .

Market Research Report on Global and Chinese Benzarone Industry, 2009-2019 is a professional and in-depth market survey on global and Chinese benzarone markets.  This report provides forecasts information on 2014-2019 Global and China Capacity, Production, and Production Value of Benzarone, 2014-2019 Benzarone Industry Cost and Profit Estimation, 2014-2019 Global and China Market Share of Benzarone, 2014-2019 Global and China Supply and Consumption of Benzarone and 2014-2019 China Import and Export of Benzarone. Complete report is available at http://www.reportsnreports.com/reports/280193-market-research-report-on-global-and-chinese-benzarone-industry-2009-2019.html .

List of Figures provided in COPD Drug Market Opportunity & Clinical Pipeline Analysis research report include:

Figure 1-1: Global - People Suffering With COPD (Million), 2013-2018

Figure 1-2: US - People Suffering With COPD (Million), 2013-2018

Figure 1-3: US - People Suffering With COPD by Age Group (%)

Figure 1-4: Europe - People Suffering With COPD (Million), 2013-2018

Figure 1-5: Europe - Death from COPD ('000) , 2005 & 2030

Figure 1-6: Global COPD Drug Market (US$ Billion), 2012-2018

Figure 1-7: Number of COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-8: COPD Drugs in Clinical Trial by Phase (%), 2014

Figure 1-9: Number of Discontinued COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-10: Discontinued COPD Drugs in Clinical Trial by Phase (%), 2014

Figure 1-11: Number of Suspended COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-12: Suspended COPD Drugs in Clinical Trial by Phase (%), 2014

Figure 1-13: Number of No Development in COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-14: No Development in COPD Drugs in Clinical Trial by Phase (%), 2014

About Us: 

ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact: 

Priyank Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
[email protected]

http://www.deepresearchreports.com/cat/pharmaceuticals-market-research.html

Connect With Us on: 

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/


SOURCE ReportsnReports.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web co...
Redis is not only the fastest database, but it has become the most popular among the new wave of applications running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 18th Cloud Expo, Dave Nielsen, Developer Relations at Redis Labs, shared the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
Amazon has gradually rolled out parts of its IoT offerings, but these are just the tip of the iceberg. In addition to optimizing their backend AWS offerings, Amazon is laying the ground work to be a major force in IoT - especially in the connected home and office. In his session at @ThingsExpo, Chris Kocher, founder and managing director of Grey Heron, explained how Amazon is extending its reach to become a major force in IoT by building on its dominant cloud IoT platform, its Dash Button strat...
"We are a custom software development, engineering firm. We specialize in cloud applications from helping customers that have on-premise applications migrating to the cloud, to helping customers design brand new apps in the cloud. And we specialize in mobile apps," explained Peter Di Stefano, Vice President of Marketing at Impiger Technologies, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
The idea of comparing data in motion (at the sensor level) to data at rest (in a Big Data server warehouse) with predictive analytics in the cloud is very appealing to the industrial IoT sector. The problem Big Data vendors have, however, is access to that data in motion at the sensor location. In his session at @ThingsExpo, Scott Allen, CMO of FreeWave, discussed how as IoT is increasingly adopted by industrial markets, there is going to be an increased demand for sensor data from the outermos...
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes how...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...